{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-021346","form_type":"8-K","ticker":"GRCE","cik":"0001444192","company_name":"Grace Therapeutics, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.891596+00:00","generated_at":"2026-06-15T03:56:20.472763+00:00","sec_items":["5.02","8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Acasti Pharma appoints new CMO, VP Clinical Ops; terminates CFO and COOs; submits GTX-104 Phase 3 plan to FDA","bullets":["Appointed Dr. R. Loch Macdonald as CMO, Carrie D'Andrea as VP Clinical Ops, Amresh Kumar as VP Program Mgmt; effective immediately or May 15.","Terminated CFO Brian Ford (interim until June 30), COO Canada Pierre Lemieux, COO US George Kottayil; severance payments.","Submitted full protocol for GTX-104 pivotal Phase 3 Safety Study to FDA; first patient dosing expected Q4 2023.","Strategic realignment focuses on GTX-104; cash runway extended through Q2 2025; evaluating alternatives for GTX-102, GTX-101.","Discontinuing Canadian operations, laying off substantially all workforce; rebuilding leaner US organization."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-021346","json":"https://secwatch.observer/filing/0000950170-23-021346.json","markdown":"https://secwatch.observer/filing/0000950170-23-021346.md","text":"https://secwatch.observer/filing/0000950170-23-021346.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1444192/000095017023021346/0000950170-23-021346-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1444192/000095017023021346/acst-20230508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T03:56:20.472763+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"02e7ea8a38","claim":"Brian Ford was terminated as Chief Financial Officer at Grace Therapeutics, Inc..","evidence_excerpt":"On May 8, 2023, the Company terminated the employment of Brian Ford, Chief Financial Officer; Pierre Lemieux, Chief Operating Officer (Canada); and George Kottayil, Chief Operating Officer (US).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1444192/000095017023021346/0000950170-23-021346-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"09498a5a02","claim":"Amresh Kumar was appointed as VP of Program Management at Grace Therapeutics, Inc..","evidence_excerpt":"On May 8, 2023, the Company appointed Amresh Kumar, PhD, as its VP of Program Management, effective May 15, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1444192/000095017023021346/0000950170-23-021346-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"VP of Program Management"}],"fact_type":"executive_change"},{"claim_id":"2a388a9555","claim":"George Kottayil was terminated as Chief Operating Officer (US) at Grace Therapeutics, Inc..","evidence_excerpt":"On May 8, 2023, the Company terminated the employment of Brian Ford, Chief Financial Officer; Pierre Lemieux, Chief Operating Officer (Canada); and George Kottayil, Chief Operating Officer (US).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1444192/000095017023021346/0000950170-23-021346-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Operating Officer (US)"}],"fact_type":"executive_change"},{"claim_id":"38c9900e52","claim":"Dr. R. Loch Macdonald was appointed as Chief Medical Officer at Grace Therapeutics, Inc..","evidence_excerpt":"On May 8, 2023, the Company appointed Dr. R. Loch Macdonald, MD, PhD, as Chief Medical Officer, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1444192/000095017023021346/0000950170-23-021346-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"77ca4a072d","claim":"Pierre Lemieux was terminated as Chief Operating Officer (Canada) at Grace Therapeutics, Inc..","evidence_excerpt":"On May 8, 2023, the Company terminated the employment of Brian Ford, Chief Financial Officer; Pierre Lemieux, Chief Operating Officer (Canada); and George Kottayil, Chief Operating Officer (US).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1444192/000095017023021346/0000950170-23-021346-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Operating Officer (Canada)"}],"fact_type":"executive_change"},{"claim_id":"e889b05091","claim":"Carrie D'Andrea was appointed as VP Clinical Operations at Grace Therapeutics, Inc..","evidence_excerpt":"On May 8, 2023, the Company appointed Carrie D'Andrea as its VP Clinical Operations, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1444192/000095017023021346/0000950170-23-021346-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"VP Clinical Operations"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}